UPSTREAM BIO, INC. (UPB) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $54.00K; Additional Paid in CapitalUSD $685.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-123.00K; Retained Earnings (Accumulated Deficit)USD $-414.52M.
- 2026-03-31: Common Stock, Value, IssuedUSD $54.00K; Additional Paid in CapitalUSD $678.65M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $100.00K; Retained Earnings (Accumulated Deficit)USD $-374.81M.
- 2025-12-31: Common Stock, Value, IssuedUSD $54.00K; Additional Paid in CapitalUSD $673.41M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $530.00K; Retained Earnings (Accumulated Deficit)USD $-334.22M.
- 2025-09-30: Common Stock, Value, IssuedUSD $56.00K; Additional Paid in CapitalUSD $669.80M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $493.00K; Retained Earnings (Accumulated Deficit)USD $-291.76M.
UPSTREAM BIO, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $54.00K | $685.54M | $-123.00K | $-414.52M | $270.96M | 3 month · $4.35M |
| 2026-03-31 | $54.00K | $678.65M | $100.00K | $-374.81M | $304.00M | 3 month · $4.65M |
| 2025-12-31 | $54.00K | $673.41M | $530.00K | $-334.22M | $339.77M | 12 month · $10.33M |
| 2025-09-30 | $56.00K | $669.80M | $493.00K | $-291.76M | $378.58M | 3 month · $2.59M |
| 2025-06-30 | $54.00K | $666.45M | $258.00K | $-258.02M | $408.74M | 3 month · $2.60M |
| 2025-03-31 | $53.00K | $663.24M | $368.00K | $-218.05M | $445.61M | 3 month · $2.63M |
| 2024-12-31 | $53.00K | $660.60M | $-25.00K | $-190.78M | $469.85M | 12 month · $6.00M |
| 2024-09-30 | $3.00K | $8.87M | $351.00K | $-169.54M | $-160.31M | 3 month · $1.86M |
| 2024-06-30 | (m) | (m) | (m) | (m) | $-146.61M | 3 month · $1.41M |
| 2024-03-31 | (m) | (m) | (m) | (m) | $-133.41M | 3 month · $643.00K |
| 2023-12-31 | $3.00K | $4.82M | $21.00K | $-127.97M | $-123.13M | 12 month · $3.33M |
| 2023-09-30 | (m) | (m) | (m) | (m) | $-112.20M | 3 month · $683.00K |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-109.87M | 3 month · $627.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-107.91M | 3 month · $1.30M |
| 2022-12-31 | (m) | (m) | (m) | (m) | $-106.16M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |